___

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.

World Health Organization Hepatitis B Fact Sheet No. 204 (Revised October 2000) https://www.who.int/en/news-room/ fact-sheets/detail/hepatitis-a (accessed in July 2018).

Visvanathan K, Lewin SR Immunopathogenesis: Role of Innate and Adaptive Immune Reponses, Semin Liver Dis 2006; 26: 104-15.

Thursz MR, Thomas HC. Pathogenesis of chronic hepatitis B. In: Thomas HC, Lemon S, Zuckermann A (Eds). Viral Hepatitis. Massachusetts; Blackwell Publishing Ltd, 2005; 308-22.

De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39(suppl 1): S3-25.

Murray JM, Wieland SF, Purcell RH et al. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 2005; 102: 17780–85.

Guidotti LG, Rochford R, Chung J et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825–29.

Herbein G, O’Brien WA. Tumor Necrosis Factor (TNF)-α and TNF Receptors in Viral Pathogenesis, PSEBM 2000; 223: 241-57.

Fang JW, Shen WW, Meager A, et al. Activation of the tumor necrosis factor-α system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol 1996; 91:748-53.

Su F, Schneider RJ. Hepatitis B virus x protein sensitizes cells to apoptotic killing by tumor necrosis factor-α. Proc Natl Acad Sci USA 1997; 94: 8744-49.

Romero R, Lavine JE. Cytokine inhibiton of hepatitis B core pro- motor. Hepatology 1996; 23: 17-23.

Tsui L V, Guidotti L G, Ishikawa T, et al. Posttranscriptional clear- ance of hepatitis B virus RNA by cytotoxic T lymphocyte-activat- ed hepatocytes. Proc Natl Acad Sci USA 1995; 92: 12398–402.

Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients:need for primary prophylaxis. Gut 2004; 53: 1363–65.

D’Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994; 39: 150–54.

Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401–06.

Fernandes H, Koneru B, Fernandes N et al. Investigation of pro- moter polymorphisms in the tumor necrosis factor-alpha and in- terleukin-10 genes in liver transplant patients. Transplantation 2002; 73: 1886–91.

Bayley JP, Ottenhoff THM and Verweij CJ. Is there a future for TNF promoter polymorphisms? Genes and Immunity 2004; 5:315–29.

Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in 6 lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401–406.

Höhler T, Kruger A, Gerken G, Shneider PP, et al. A tumour necrosis factor alpha (TNFα) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998; 111: 579-82.

Miyazoe S, Hamasaki K, Nakata K, et al. Influence of Interleukin 10 gene promotor polimorphisms on disease progression in patients chronically infected with Hepatitis B virus. The American Journal of Gastroenterology 2002; 97: 2086-92.

Lu LP, Li XW, Liu Y, et al. Association of -238G/A polimorphism of tumour necrosis factor alpha gene promoter region with out- comes of hepatitis B virus infection in Chinese Han population. World J Gastroenterol 2004; 10: 1810-14.

Li HQ, Li Z, Liu Y, et al. Association of polymorphism of tumour necrosis factor alpha gene promoter region with outcome of hepatitis B virus infection. World J Gastroenterology 2005; 11: 5213-17.

Du T, Guo XH, Zhu XL et al. Association of TNF-alpha promot- er polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population. Journal of Viral Hepatitis 2006; 13: 618-24.

Li Chen, Zhi Xin C, Li-Juan Zm, et al. The association between cytokine polimorphisms ant the outcomes of chronic HBV infection. Hepatology Research 2006; 36: 158-66.

Niro GA, Fontana R, Gioffreda D, et al. Tumour necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver International 2005; 25: 1175-81.

Kim YJ, Lee HS, Yoon JH, et al. Association of the TNF-α promoter polymorphisms with the clearance of hepatitis B virus infection Human Molecular Genetics 2003; 12(19): 2541-46.

Mıstık R. Türkiye’de viral hepatit epidemiyolojisi yayınların ird- elenmesi. In: Tabak F, Balık İ, Tekeli E (eds). Viral Hepatit 2007. Viral Hepatitle Savaşım Derneği, İstanbul, Turkey: Ohan Publications, 2006, 10-50.

Höhler T, Geeken G, Notghi A, et al. HLA-DRB1*1301 and 1302 protect against chronic hepatitis B. J Hepatol 1997; 26: 503-07.

[29] Wang C, Tang J, Song W, et al. HLA and cytokine gene poly- morphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004; 39: 978 –88.

[30] Ozen S, Alikasifoglu M, Bakkaloglu A, et al. Tumor necrosis factor α G→A -238 and G→A -308 polymorphisms in juvenile idio- pathic arthritis. Rheumatology 2002; 41: 223-27.

Karahan ZC, Deda G, Sipahi T, et al. TNF-A —308G/A and IL-6 -174 G/C polymorphisms in the Turkish pediatric stroke patients. Thrombosis Research 2005; 115; 393-98.

Sghaier I, Zidi S, Mouelhi L, et al. The relationship between TNF alpha gene polymorphisms (− 238/− 308), TNF RII VNTR (p75) and outcomes of hepatitis B virus infection in Tunisian popula- tion. Gene 2015; 568: 140-45.

Valaydon Z, Pellegrini M, Thompson A, et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clinical & Translational Immunology 2016; 5(12): e115.